## Claims

1. A dicarboxylic acid salt of sibutramine, represented by the following Chemical Formula 1:

Chemical Formula 1

5

wherein, n is an integral number of 0 or 1.

2. The dicarboxylic acid salt of sibutramine as set forth in claim 1, which is sibutramine oxalate having an X-ray diffraction pattern in which peaks appear at 2θ values

10 of 5.46, 10.92, 12.16, 12.74, 14.92, 15.44, 15.78, 17.4, 19.24, 21.3, 22.0, 22.92, 24.54, 25.3, 25.8, 27.52, 28.74, 28.92, 30.12, 33.26, 35.04, and 39.76.

3. The dicarboxylic acid salt of sibutramine as set forth in claim 1, which is sibutramine malonate having an

15 X-ray diffraction pattern in which peaks appear at 2θ values of 7.7, 10.74, 11.08, 11.56, 15.42, 15.78, 17.24, 17.84, 18.1, 19.02, 19.68, 21.54, 21.9, 22.24, 22.88, 23.26, 23.64, 24.44, 24.72, 26.0, 27.6, 28.4, 28.62, and 29.3.

4. A method of preparing the dicarboxylic acid salt of sibutramine represented by Chemical Formula 1 according to claim 1, comprising reacting sibutramine with a dicarboxylic acid selected from among oxalic acid and

5   malonic acid in an inert solvent.

5. A pharmaceutical composition for treating or preventing obesity and related disorders, depression, Parkinson's disease, insulin-independent diabetes mellitus or epilepsy, comprising the dicarboxylic acid salt of

10   sibutramine represented by Chemical Formula 1 according to claim 1 as an effective ingredient.

6. The pharmaceutical composition as set forth in claim 5, which is formulated into tablets or capsules.

7. A method of treating or preventing obesity and

15   related disorders, depression, Parkinson's disease, insulin-independent diabetes mellitus or epilepsy, comprising administering the pharmaceutical composition of claim 5.